Top

Published in:

01-06-2020 | Perspective

Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab

Authors: S.R. Cummings, C. McCulloch

Published in: Osteoporosis International | Issue 6/2020

Excerpt

Romosozumab, an anti-sclerostin antibody, has been approved for prescription in the USA, Europe, Japan, and South Korea to treat patients with osteoporosis who have a high risk of fracture. The Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk (ARCH) trial randomly assigned women to receive alendronate or romosozumab for 12 months. It found a difference between the alendronate and romosozumab group in the incidence of major cardiovascular events (CVD), also defined as adjudicated major adverse cardiovascular events (MACE) [1]. After 12 months, those in the alendronate group continued alendronate for a median of 33 months and those assigned to romosozumab switched to alendronate for the duration of the trial. …

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427CrossRef

Fayers PM, Ashby D, Parmar MK (1997) Tutorial in biostatistics Bayesian data monitoring in clinical trials. Stat Med 16(12):1413–1430CrossRef

U.S. Food and Drug Administration, Amgen Inc. Amgen presentations: Cardiovascular Safety; Meeting of the bone reproductive and urologic drugs advisory committee. January 16, 2019. Accessed at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/january-16-2019-meeting-bone-reproductive-and-urologic-drugs-advisory-committee-meeting-announcement. Accessed Jan 2020

Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W (2016) Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis. 252:106–115CrossRef

U.S. Food and Drug Administration. FDA Briefing information document: Meeting of the bone reproductive and urologic drugs advisory committee. January 16, 2019: page 35. Accessed at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/january-16-2019-meeting-bone-reproductive-and-urologic-drugs-advisory-committee-meeting-announcement. Accessed Jan 2020

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture prevention with Zoledronate in older women with osteopenia. N Engl J Med 379(25):2407–2416CrossRef

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543CrossRef

Title: Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab
Authors: S.R. Cummings
C. McCulloch
Publication date: 01-06-2020
Publisher: Springer London
Published in: Osteoporosis International / Issue 6/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-020-05379-z

At a glance: The STEP trials

Springer Medicine

Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2020

Describing the resource utilisation and costs associated withvertebral fractures: the Build Better Bones with Exercise (B3E) Pilot Trial

Correction to: Effects of a resistance and balance exercise programme on physical fitness, health-related quality of life and fear of falling in older women with osteoporosis and vertebral fracture: a randomized controlled trial

Insulin resistance negatively affects bone quality not quantity: the relationship between bone and adipose tissue

The relationship between atherosclerosis and bone mineral density in patients with type 2 diabetes depends on vascular calcifications and sex

Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study

Depression, falls, and fractures